All In Biotech

Drug Trial Radar · NCT00044785

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

A Phase I Study of Escalating Doses of CPT-11 and 5fluorouracil (5FU) Plus PN401 With a Fixed Dose of Leucovorin in Patients With Solid Tumor Malignancies.

Last checked: Nov 20, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

24

Actual

Start

Aug 2002

Primary completion

Not stated

Study completion Mar 2004

Sponsor

Lead sponsor
Wellstat TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 6, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential. It is hypothesized that adding PN401 to the CPT-11, 5FU, leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well tolerated and therefore potentially increase effectiveness.

Conditions

  • Solid Tumors

Interventions

  • triacetyluridineDrug

  • fluorouracilDrug

  • leucovorinDrug

  • camptosarDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Maximum Tolerated Dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Maryland, Greenebaum Cancer Center

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.